NewLimit raises $435M to take cell-reprogramming into humans Armstrong-backed longevity firm reports age reversal in human liver cells, jumps to a $3.1B valuation and a first clinical trial Whose Money ·9 takes ·Jun 24
Retro Biosciences raises at $1.8B as Alzheimer's trial advances Altman-backed longevity firm marks down from a mooted $5B but its first pill clears early safety; data due ~August Whose Money ·6 takes ·Jun 24
